| Literature DB >> 12374215 |
S Martino1, C Cavalieri, C Emiliani, D Dolcetta, M G Cusella De Angelis, V Chigorno, G M Severini, K Sandhoff, C Bordignon, S Sonnino, A Orlacchio.
Abstract
The therapeutic potential of bone marrow-derived stromal cells for the therapy of Tay-Sachs disease is primarily related to the restoration of their own GM2 ganglioside storage. With this aim, we produced bone marrow-derived stromal cells from the adult Tay-Sachs animal model and transduced them with a retroviral vector encoding for the alpha-subunit of the lysosomal enzyme beta-hexosaminidase A (E.C. 3.2.1.52). Our results demonstrate that transduced Tay-Sachs bone marrow-derived stromal cells have beta-hexosaminidase A comparable to that of bone marrow-derived stromal cells from wild-type mice. Moreover, beta-hexosaminidase A in transduced Tay-Sachs bone marrow-derived stromal cells was able to hydrolyze the GM2 ganglioside in a feeding experiment, thus demonstrating the correction of the altered phenotype.Entities:
Mesh:
Substances:
Year: 2002 PMID: 12374215 DOI: 10.1023/a:1020256924099
Source DB: PubMed Journal: Neurochem Res ISSN: 0364-3190 Impact factor: 3.996